paul_chew_medlo

Sanofi appoints Paul Chew as chief medical officer

pharmafile | October 1, 2012 | Appointment | Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Paul Chew, Sanofi 

Sanofi has appointed Dr Paul Chew as chief medical officer and head of global medical affairs.

Taking up his post on 1 January 2013, the current senior vice president, chief science officer and chief medical officer at Sanofi in the US, will succeed Jean-Pierre Lehner, who is to retire on 31 December.

Chew will report to Dr Elias Zerhouni, president of global R&D at the French pharma group, and will be based in New Jersey and Paris.

Advertisement

“The knowledge and experience Paul has gained through his previous roles, including his work as a cardiologist, his expertise in diabetes and work within R&D make him ideally suited,” said Zerhouni.

Chew has been in his current role since January 2009, before which he was president of US R&D at the company. Before joining Sanofi he held various roles, including global head of metabolism and diabetes at Aventis Pharmaceuticals.

He worked for Bristol-Myers Squibb between 1992 and 2001, and moved into the pharma industry from academia: he was assistant professor of medicine at The Johns Hopkins Hospital.

Lehner retires after 20 years at Sanofi and his chief executive Christopher Viehbacher said he had “made significant and lasting contributions to improve public health and has been a key contributor to Sanofi’s success”.

Related Content

Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria

Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …

Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition

The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) …

sanofi

Sanofi completes acquisition of Vigil Neuroscience to early neurology pipeline

Sanofi has announced that it has finalised its acquisition of Vigil Neuroscience, a US-based biotechnology …

The Gateway to Local Adoption Series

Latest content